My earlier link didn't work. Check out this 3 mo comparison in performance for SCLN, REGN, DSCO, CEGE and DNDN. Also go back 6 mo to see how their performance played out over that time frame. DNDN and CEGE are underperforming the others from their March-April lows. Seems to indicate that market doesn't have as much confidence in their trials and/or therapeutic and vaccine approach to cancers. Time will tell whether the market has misjudged DNDN. All I can say is that DNDN is building a very strong base in the $5-6 dollar range. My bets have been placed.
News 
Market Data 
Discover 
